VIA
CLVS

Vident Investment Advisory’s Clovis Oncology, Inc. CLVS Stock Holding History

Vident Investment Advisory’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-42,347
Closed -$1.48M – 394
2015
Q4 		$1.48M Buy
42,347
+15,062
+55% +$971K 0.19% 251
2015
Q3 		$2.51M Buy
27,285
+6,759
+33% +$585K 0.35% 39
2015
Q2 		$1.8M Buy
+20,526
New +$1.76M 0.24% 106

Other funds holding CLVS

PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vident Investment Advisory's CLVS Position: Q1 2016 in Review

Vident Investment Advisory sold out of Clovis Oncology, Inc. (CLVS) in Q1 2016, closing a stake of 42,347 shares — an estimated $1.48M sold.

Vident Investment Advisory first reported a position in CLVS in Q2 2015 and held it in 3 quarters. The position peaked at $2.51M in Q3 2015. 135 funds tracked by Wall St. Rank hold CLVS as of Q1 2016.

  • Vident Investment Advisory reported no remaining Clovis Oncology, Inc. position as of Q1 2016 after selling out during the quarter.
  • Vident Investment Advisory sold 42,347 Clovis Oncology, Inc. shares in Q1 2016, an estimated $1.48M.
  • Vident Investment Advisory first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 3 quarters.
  • Vident Investment Advisory's Clovis Oncology, Inc. position peaked at $2.51M in Q3 2015.
  • 135 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2016.

Based on Vident Investment Advisory's 13F filing for Q1 2016, filed 23 May 2016.